CAMBRIDGE, Mass .– (COMMERCIAL THREAD) – Rheos Medicines (Rheos), a biopharmaceutical company that harnesses knowledge in immunometabolism to create a new therapeutic class for patients with severe autoimmune disorders, inflammatory diseases and cancer, today announced that it has entered into a worldwide exclusive collaboration, option and license agreement with Roche to discover, develop and commercialize novel therapies in the field of immunmetabolism.
“We are delighted to leverage our expertise in human immune cell metabolism in partnership with Roche,” said Barbara Fox, CEO of Rheos. “We believe that our team’s extensive experience in immunology and cell metabolism as well as our unique approach has the potential to unlock a new frontier in precision medicine for immune-mediated diseases. This partnership will help accelerate the translation of knowledge in immunometabolism towards the development of breakthrough therapies for patients with autoimmune and inflammatory diseases. ”
“We are delighted to partner with Rheos and look forward to the development of a new therapeutic class for patients with autoimmune and inflammatory diseases,” said Gijs van den Brink, SVP and Global Head of Immunology, Infectious Diseases and Ophthalmology at Roche Pharma Early Research and Development: “We believe that Rheos’ proprietary platform and expertise in immunometabolism strongly complements Roche’s expertise in autoimmunity and inflammation, as well as in the development and commercialization of innovative therapies.
Under the terms of the agreement, Rheos will lead a proprietary research effort to identify new targets in immunometabolism that alter the fate or function of certain human immune cells. In addition, Rheos will also be responsible for the drug discovery efforts as part of the collaboration. Roche will receive an exclusive license option for a defined number of programs resulting from the collaboration. For some products of the collaboration, Rheos and Roche may share global development and commercial rights in the United States.
Rheos will receive an initial cash payment of $ 42.5 million upon execution and will be eligible to receive up to approximately $ 90 million for specified preclinical research and development milestones as well as an option fee. Rheos will also be eligible to receive up to approximately an additional $ 660 million in specific development, regulatory and sales milestones across programs and tiered royalties on net sales. For products for which Rheos and Roche may share the development and commercial rights, Rheos will be entitled to additional financial compensation in the United States and outside the United States in proportion to the share of its financial investment in development and commercialization.
About Rheos Medicines
Rheos Medicines is a biopharmaceutical company that harnesses knowledge in immunometabolism to develop novel therapies for patients with severe autoimmune diseases, inflammatory diseases and cancer. Our approach targets the underlying intracellular metabolism of immune cells and has the potential to unlock a new frontier in drug discovery for immune-mediated diseases. Using a proprietary platform and product engine that integrates multiple ‘omics’ data sets, we systematically define the biological links between metabolism and immune cell function and simultaneously identify new drug targets and disease biomarkers. to provide precision in the treatment of immune-mediated diseases. We have brought together leading scientists whose discoveries have opened up the field of immunmetabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced biotechnology management team. Rheos was founded by Third Rock Ventures and is located in Cambridge, MA. For more information, please visit www.rheosrx.com.